NO Image

6th International Conference on Oncology and Precision Medicine

Dec 05-06, 2024

|

Dubai, United Arab Emirates (UAE)





Oncology Meeting 2023



The Future of Oncology: Emerging Technologies and Treatment Strategies


6th International Conference on Oncology and Precision Medicine is an award-winning international conference that encourages effective knowledge transfer and best practices exchange amongst over 250 cancer control and public health experts from 50 countries. It aims to strengthen the participant’s action and impact on national, regional, and international scales through a multidisciplinary program that features the latest successful interventions in cancer prevention, diagnosis, treatment, and care.

 

Cancer and Radiotherapy Conference

We invite scientists, researchers, educators and students, industry, investors, and people from all walks of life who are interested in Cancer Science Research to attend the conference and share their experiences and innovations with others, as well as explore opportunities for collaboration.

About Cancer and Radiotherapy

The 6th International Conference on Oncology and Precision Medicine is scheduled for December 05-06, 2024 in Dubai, UAE. Cancer Conference 2024 runs with the theme “The Future of Oncology: Emerging Technologies and Treatment Strategies”. We are beaming to welcome all the leading researchers, delegates, scientists, scholars, and professors to take part in this approaching conference to witness precious scientific discussions and bestow future innovations in the treatment in the field of Cancer, Oncology. This Conference will emphasize the informative research on its impact on clinical outcomes, through poster and oral demonstrations, educational workshop sessions, and noteworthy plenary presentations. Cancer Conference is a perfect podium to find out how cancer research advances obliging the Medical, Health, and human society. Cancer Conference will principally highlight the recent matters during the event, which reflect present education, developments, research, and innovations globally in the field of cancer, oncology, and medical sectors.

 

WHY SHOULD YOU ATTEND?

  • Participate in one of the most powerful connecting platforms in cancer conference.
  • Raise your voice on a global stage and contribute to accelerating progress in the fight against cancer - here
  • Engage in person with the most influential experts and leaders in global cancer and radiotherapy conference
  • Make valuable and inspirational connections through facilitated networking 
  • Join one of the education and training opportunities offered as part of the program

Download Conference Brochure: 

Registration is now open for Cancer Conference 2024. The Scientific Program Committee is formalizing the program schedule, which will provide ample opportunities for networking with colleagues and old friends in the Cancer Research World.

 

Early Bird Registration End: July 24, 2024 (ON OR BEFORE)

Advance Booking : August 21, 2024 ( ON OR BEFORE)

On-Site Booking: December 05, 2024 (ON OR BEFORE)

 

We have special collobration with Onkologia I Radioterapia is an international peer reviewed journal which publishes on both clinical and pre-clinical research related to cancer. You can publish your full article at Onkologia i Radioterapia (ISSN 1896-8961) at Low article publishing charge.

Indexed and Abstracted with: 
 SCOPUS | SCImago | MIAR | Cancer Index | Medical Project Poland |  Russian Science Citation Index (RSCI) Powered by Clarivate Analytics

 

 

PARTICIPATION OPTIONS

Cancer Conference 2024 provides the participants with different modes or ways to participate such as Delegate or Speaker under ACADEMIC / STUDENT / BUSINESS Category. 

1.    Keynote speaker: 45-50 minutes

2.    Speaker (oral presentation): 25-30 minutes (only one person can present)

3.    Speaker (workshop): 45-50 minutes (more than 1 can present)

4.    Speaker (special session): 45-50 minutes (more than 1 can present)

5.    Speaker (symposium): more than 45 minutes (more than 1 can present)

6.    Delegate (only registration): will have access to all the sessions with all the benefits of registration

7.    Poster presenter:  can present a poster and enjoy the benefits of delegate

8.    Remote attendance:  can participate via video presentation or e-poster presentation

9.    Exhibitor: can exhibit his/her company’s products by booking exhibitor booths of different sizes

10.  Media partner

11.  Sponsor

12.  Collaborator

 

Market Analysis

Cancer is a global health problem that affects people of all ages, genders, and ethnicities. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for an estimated 14.6 million deaths in 2023. The incidence of cancer is also increasing globally, with an estimated 18.1 million new cases and 14.6 million deaths from cancer in 2023.

The global cancer market is expected to grow at a significant rate due to several factors such as the increasing aging population, changing lifestyles, growing awareness about cancer, and technological advancements in cancer treatment. In 2023, the global oncology market was valued at USD 150.0 billion and is expected to reach USD 297.3 billion by 2026, at a CAGR of 8.7% during the forecast period.

The market analysis of cancer patients in different regions shows that the burden of cancer is highest in low- and middle-income countries. According to WHO, more than 70% of cancer deaths occur in these countries, despite having lower cancer incidence rates compared to high-income countries. The most common cancers in low- and middle-income countries are breast, cervical, and lung cancer, while prostate, colorectal, and lung cancer are the most common in high-income countries.

In terms of cancer treatments, chemotherapy, and radiation therapy are the most commonly used methods of cancer treatment worldwide. However, targeted therapy and immunotherapy are gaining popularity due to their ability to target cancer cells more precisely, with fewer side effects.

Overall, the global cancer market is expected to continue to grow due to the increasing prevalence of cancer, the aging population, and technological advancements in cancer treatment. However, the burden of cancer remains highest in low- and middle-income countries, highlighting the need for increased access to cancer prevention, screening, and treatment in these regions.

The Asia-Pacific cancer therapy market is expected to observe good growth owing to the rising prevalence of cancer, growing government initiatives for cancer awareness, and increasing patient assistance programs (PAPs). Lung, stomach, colorectum, liver, and esophagus are the most common types of cancer in China. The increasing prevalence of cancer burden and thus, cancer therapies is due to a number of factors, including population growth, aging, environmental pollution, and unhealthy dietary habits. In addition, cigarette smoking, in particular, has also continued to be prevalent in the Asia-Pacific region. The rising prevalence of cancer, thus helps the market to grow over the forecast period. The target therapy segment is expected to show a good CAGR over the forecast period. The targeted therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells.

The other major factors driving the growth of the segment are an increase in R&D and the rising prevalence of various types of cancer across the globe. Targeted therapy is a treatment for cancer that is unlike the traditional chemotherapy used for cancer. The drugs for target therapy work by targeting the specific genes or proteins that are present in the cancer cells. 

The global cancer burden increased to 19.3 million cases and 10 million deaths in 2020, according to new estimates from the International Agency for Research on Cancer's Global Cancer Observatory, and is expected to rise to more than 30 million cases and over 16 million deaths by 2040, with the majority of the increases occurring in low- and middle-income countries. Cancer incidence and mortality are increasing globally due to ageing populations, limited access to preventive and oncology care services, a shortage of cancer specialists, late-stage disease presentation, medicines, and diagnostic equipment, obesity, and lifestyle choices. Cancer treatment has traditionally been regarded as one of the most important and significant clinical topics. Depending on the type and stage of cancer, a variety of approaches have been developed. It's high time for us to start providing high-quality cancer care to low-resource areas.

Our forthcoming conference will strike up conversations on the present status of cancer treatment and provide an interactive forum to hear about policies and neoteric changes that are being implemented to help reduce cancer treatment backlogs and, ultimately, improve the health of cancer patients. This two-day conference will provide a timely opportunity to hear from, learn from, and interact with some of the World's finest oncology professionals while networking with like-minded peers.

The agenda of the Cancer Congress 2022 is to promote discoveries, evaluate the system and strategic issues, and develop and maintain basic systems between analysts, experts, arrangement producers, and healthcare agents through its plenary talks, keynote sessions, oral and poster presentations. We've invited some of the world's most influential speakers including researchers, scientists, oncologistscancer specialists, pharmacists, clinicians, academicians, young scholars, healthcare professionals, policymakers and industry representatives to provide motivational presentations and workshops.

Join us at Cancer Conference 2022 for an interactive environment aimed at improving cancer patient outcomes.

Last Conference Gallary

Lucy
Karol Sikora
Proton Partners International Limited United Kingdom

Biography

Karol Sikora is Chief Medical Officer of Proton Partners International. He was the founder of Cancer Partners UK which has created UK’s largest independent UK cancer network with private equity. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and a Fellow of Corpus Christi College, Cambridge. He has published over 300 papers and written or edited 20 books including Treatment of Cancer - the standard British postgraduate textbook, now in its sixth edition. His new book for patients The street-wise patient’s guide to cancer survival has just been published.

Lucy
Diana Anderson
Head and Professor
University of Bradford

Biography

Professor Anderson holds the Established Chair in Biomedical Sciences at the University of Bradford. She obtained her first degree in the University of Wales and second degrees in the Faculty of Medicine, University of Manchester. She has an H index of 57, 450+ peer-reviewed papers, 8 books, has successfully supervised 26 PhDs, and been a member of editorial boards of 10 international journals. She has been or is Editor in Chief of a book Series on toxicology for J.Wiley and sons and the Royal Society of Chemistry respectively. She gives key note addresses at various international meetings. She is a consultant for many international organisations, such as the WHO, NATO, TWAS, UNIDO and the OECD.

Lucy
Shahla Masood
Professor and Chair
University of Florida

Biography

Dr. Kumar received his Ph.D. degree in Neuro-toxicology and is currently a Professor of Biochemistry at The Commonwealth Medical College, Scranton, PA, USA. Dr. Kumar’s research area is focused on the therapeutic targeting of the steroid receptors (SRs) for endocrine-related cancers. Currently, his laboratory is working on a novel therapeutic strategy that could provide cell/tissue-specific target gene regulations in current SHR-based endocrine therapies. In addition to more than 100 publications to his credit, Dr. Kumar has also served as Editorial Board member of more than two-dozen scientific journals, and as expert reviewer on more than two-dozen grant review panels.

Lucy
Dr Ivan Terziev
Head of Pathology DepartmentAssociate Professor
ISUL University Hospital

Biography

Dr Ivan Terziev was born in 1961. He graduated in Medicine in 1987 from the Medical University of Sofia and obtained a specialty in Pathology and Cytology in 1991. Dr Terziev has been working at Tsaritsa Yoanna ISUL University Hospital since 1988, and he is also an Assistant professor of Pathology at the Medical University of Sofia, Bulgaria. Dr Terziev is a member of Bulgarian and European Society of Pathology and Bulgarian-Turkish group on Diseases of Thyroid and Breast. He has numerous publications in Bulgarian scientific journals, as well as more than 20 papers in reputed international ones. Dr Terziev is working in the area of histopathology of head of neck, thyroid gland, gastrointestinal, breast and surgical pathology

Lucy
Ragheed Al-Mufti
Chairman
The West of London Breast Cancer Network

Biography

A Jain has completed his PhD from Agra University, India. He was a visiting scientist at Texas A&M University. Currently he is a Professor at Albany State University, GA and program coordinator for Biotechnology program. He has received research funding from NIH, DOD and USDA. He served as Director, Center for Undergraduate Research and currently he is serving as MARC U*STAR project director. He has published more than 25 papers in reputed journals and has been serving as reviewer for six journals of international repute

Lucy
Federico Cattin
Breast Surgeon
Sterzing General Hospital Italy

Biography

Federico Cattin has completed his graduation at the age of 25 in the Udine University, and post-graduate studies in the Surgical Department of the same University. He is engaged in the studies about breast cancer and has attended a scholarship in the European Institute of Oncology (IEO) in Milan, held by Prof. Umberto Veronesi. He has published 13 papers in reputed journals. Nowadays he works in the Sterzing General hospital in South Tyrol, in Italy

Lucy
Colleen Huber
Co-Founder and Secretary
Naturopathic Medical Doctors of Arizona USA

Biography

Colleen Huber is a Naturopathic Medical Doctor in private practice in Tempe, Arizona. She is Co-Founder and Secretary of the American Naturopathic Research Institute/Naturopathic Oncology Research Institute (ANRI / NORI). She is a Fellow of the Naturopathic Oncology Research Institute. She is a credentialed physician at Plaza Healthcare in Scottsdale, AZ, a 179-bed in-patient, sub-acute facility, where she practices up to the full-scope of practice for naturopathic physicians licensed in Arizona. She graduated from Southwest College of Naturopathic Medicine in Tempe. Her academic writing has appeared in The L ancet and other medical journals.

Lucy
Amila Orucevic
University of Tennessee Medical Center USA

Biography

Prof. Kathy Qian Luo received BS, MS from Peking University and Ph.D. from the University of British Columbia in Canada. After finishing Postdoc research at California Institute of Technology in USA, she was working as a Visiting Assistant Professor in the Hong Kong University of Science and Technology and an Associate Professor in Nanyang Technological University of Singapore. Prof. Luo now is a Full Professor in the Faculty of Health Sciences at the University of Macau. She has published 70 journal articles with total citations of 2,000 and h-index of 25. She obtained 7 patents from USA, China, and Singapore.

Lucy
Yvone Paterson
University of Pennsylvania USA

Biography

Dr Ivan Terziev was born in 1961. He graduated in Medicine in 1987 from the Medical University of Sofia and obtained a specialty in Pathology and Cytology in 1991. Dr Terziev has been working at Tsaritsa Yoanna ISUL University Hospital since 1988, and he is also an Assistant professor of Pathology at the Medical University of Sofia, Bulgaria. Dr Terziev is a member of Bulgarian and European Society of Pathology and Bulgarian-Turkish group on Diseases of Thyroid and Breast. He has numerous publications in Bulgarian scientific journals, as well as more than 20 papers in reputed international ones. Dr Terziev is working in the area of histopathology of head of neck, thyroid gland, gastrointestinal, breast and surgical pathology.

 

Lucy
Jehad Zweiri
University of Liverpool School of Medicine

Biography

Jehad Zweiri, lecturer in Cancer studies at the University of Liverpool Medical School, born and grew up in Jordan and received his Bachelor’s degree from the University of Jordan in 1990. He obtained his master degree from London School of Hygiene and Tropical Medicine/University of London, and then obtained his PhD degree in 2000 from Kings College Medical School/University of London, in the field of Immune Gene Therapy of Cancer under the supervision of Professor Farzin Farzaneh. He then started his work as Postdoctoral Associate at the department of Immunology and Medicine at the University of Liverpool in 2002. In 2010 he was appointed as a lecturer in the university of Liverpool medical school and he is currently fellow of the British Higher Education Academy since 2012.

Lucy
Dr Arthur J De Luigi
Georgetown University

Biography

Arthur Jason De Luigi, DO, MHSA is the Chair of the Department of Physical Medicine & Rehabilitation, and Director of Sports Medicine for the Mayo Clinic Arizona. Dr. De Luigi is board certified in Physical Medicine and Rehabilitation (PM&R), Sports Medicine, Brain Injury Medicine, Pain Medicine, and Musculoskeletal Ultrasound.

Researches :

  • Sports Medicine, Musculoskeletal Ultrasound, Concussions, Musculoskeletal Injuries, and Ultrasound & Fluoroscopic Guided Interventional Spine, Joint, and Nerve procedures
Lucy
Dr Paolo Roberti di Sarsina
University of Milano-Bicocca

Biography

Dr. Paolo Roberti di Sarsina Graduated in Medicine in 1979 at the University of Bologna School of Medicine and specialized in Psychiatry in 1983 at the same University. From 1980 to 2012 full-time psychiatrist in the National Health Service at the Bologna Local Health Authority, Mental Health Service, practising as a clinical psychiatrist, psychotherapist and integrating Homotoxicology and other Non Conventional Medicine into the Italian NHS. Founder of the not-for-profit network Permanent Committee of Consensus and Coordination for Non-Conventional Medicine in Italy (established in Bologna on December 5, 2003 among the signatories to the Consensus Statement that coordinated until March 20, 2009; Committee Chairperson for International Relations. 

Researches :

  • Complementary & Integrative Medicine.
Lucy
Dr Prashant P Chaudhari
D Y Patil School of Engineering, Pune

Biography

He has published many research articles in international journals and filed several patents.  Also, he is author of two international books. He is member of editorial board  of many reputable scientific journals and serves as a reviewer for various prestigious journals. He is member of the organizing committee's numerous international conferences in Asia, Europe and North America. He has received “Best Teacher Award” by Dr D Y Patil Knowledge City, Pune. He has honored by "Excellent Researcher Award (Male)” by "International Academic and Research Excellence Awards (IARE-2019)”. During his research, he has Synthesized 78 organic compounds (By conventional & green method) out of which 76 compounds are novel compounds. He used PbO Nanoparticles for the synthesis of Azo compounds.

Researches :

  • Organic Chemistry, Green Chemistry, Environmental Engineering, Geotechnical Engineering and Nanotechnology.
Lucy
Dr Kevin Yap
La Trobe University

Biography

Dr. Kevin Yap is an inter-disciplinary cyber-pharmacist and digital health researcher at the Department of Public Health, La Trobe University. He has knowledge in digital media creation, web databases, data mining and analytics. His interests span the whole digital healthcare innovation cycle through the development, utilization, application and/or evaluation of informatics, internet, digital and other health-related technologies in various healthcare settings to enhance medications management in patients, as well as the flow of drug-related information and knowledge to healthcare professionals and patients. These include drug databases, mobile apps, prediction of adverse drug reactions, telemedicine/telepharmacy, social media, virtual platforms, and serious games, among others, to enhance health education, medicines use and improve patient care.

Researches :

  • Digital healthcare & E-health, Tele-medicine & M-health, Pharmaco-informatics & Cybernetic pharmacy, Social media in healthcare, Onco-informatics, CAM (Complementary and Alternative Medicine) Informatics and Digital education & E-learning.
Lucy
Der WONG Wai-Shiu

Biography

Dr. WS Fred Wong is a pharmacist by training. He graduated with a BS in Pharmacy (Cum Laude) from the St. John’s University College of Pharmacy and Allied Health in New York. After completing his pharmacy internship, he moved on to pursue his graduate study in The Ohio State University in Columbus, Ohio, majoring in Pharmacology. Subsequently, he did his postdoctoral training in Lilly Research Laboratory in Indianapolis, Indiana. He then moved to Brigham and Women’s Hospital of the Harvard Medical School in Boston, Massachusetts, as a research associate in medicine to study the role of urokinase in inflammatory conditions. He has joined the Department of Pharmacology of the Yong Loo Lin School of Medicine at the National University of Singapore since 1995.

Researches :

  • Allergy and Respiratory Medicine : Asthma and Airway Management Immunology : Inflammation
Lucy
Dr Vera Sau-Fong CHAN
The University of Hong Kong

Biography

Dr. Vera SF Chan is a cellular immunologist. In receiving the Croucher Foundation Scholarship, She obtained her PhD training in the area of T cell immunology in autoimmunity at the University of Oxford, UK.  Dr. Chan then continued post-doctoral training to study T cell activation and tolerance mechanisms in autoimmunity at the Ontario Cancer Institute, University of Toronto with the support of the Croucher Foundation Fellowship. In 2006, she was recruited as a Lecturer at Imperial College London, UK and in 2010, she re-joined her alma mater in Department of Medicine, the University of Hong Kong. Over the years, Dr. Chan has broadened her research interest in innate receptors, specifically in the role of the C-type lectin pathogen receptors DC-SIGN and L-SIGN in infectious diseases.  She is currently an Assistant Professor in the Division of Rheumatology and Clinical Immunology, with the research focus on the cellular immuno-dysregulation in lupus pathogenesis and innate receptor immunology.

Researches :

  • Innate receptors immunobiology, Molecular profiling, Molecular and cellular immunology
Lucy
Dr Gerard E Mullin
Johns Hopkins Hospital

Biography

Dr. Mullin is an associate professor in the department of medicine at The Johns Hopkins Hospital. He is an internist, gastroenterologist and nutritionist. Dr. Mullin is nationally and internationally renowned for his work in integrative gastroenterology and nutrition. Mullin has accumulated over 20 years of clinical experience in the field of integrative gastroenterology and earned his master’s degree in nutrition while in practice. In 2009 he was named by the American Dietetic Association’s as an honorary member. He is an associate editor of several nutrition and integrative medicine journals and serves on several exam boards. Dr. Mullin has authored/edited several books in nutrition and integrative medicine (http://thefoodmd.com/books). He has been interviewed on radio and television and has contributed to many stories in print media. Dr. Mullin’s biography has been included in Marquis Whos Who numerous times and continues to be selected as one of America’s Top Physicians since 2004.

Researches :

  • Nutrition, Gastroenterology, CAM-Integrative Medicine, Obesity/weight loss, Capsule Endoscopy, Parenteral and enteral-based nutrition support, Functional Bowel Disorders, Inflammatory Bowel Disease.
Lucy
Dr Vural Fidan
Gazi University Hospital

Biography

Dr Vural Fidan has recieved his MD and PhD in Hacettepe University. He is deputy director of ENT department. He is an Otorhinolaryngologist at Yunus Emre Goverment Hospital. He worked as a visiting scientist at Yale University ENT and Allegry departments. He has more than 20 SCI indexed articles. Research interests are pulmonary hypertension, allergy, otology, rhinology and sleep medicine.

Lucy
Dr Chandradhar Dwivedi
South Dakota State University

Biography

Dr. Chandradhar Dwivedi earned his Ph.D. degree from the Pharmacology Department of King George Medical College, Lucknow University, Lucknow, India in 1972. He was a Postdoctoral fellow at Vanderbilt University, Nashville, TN, USA. He served as faculty member at Meharry Medical College, Nashville, TN, and Research Scientist at the Ohio State University, Columbus, OH. He has been a faculty member at the Department of Pharmaceutical Sciences, College of Pharmacy, South Dakota State University (SDSU) since 1987. He was awarded the title of Distinguished Professor in 2000 and serving as Head of the Department of Pharmaceutical Sciences since Fall 2003. He is also serving as a Director of Translational Cancer Research Center funded by the State of South Dakota. His current research areas are on neuropharmacology, and cancer prevention and treatment.

Researches :

  • Pharmacology, toxicology, and pathophysiology
Lucy
Dr Masa-Aki Shibata
Japan

Biography

Dr. Shibata is a professor in Graduate School of Health Sciences, Osaka Health Science University, Osaka, Japan. He obtained doctor degree of medical sciences from Graduate School of Medical Science, Nagoya City University, Nagoya, Japan. After this he investigated cancer development and cancer prevention in National Institutes of Health, USA (1994-1999). He was awarded at the title of NIH Fellows Award for Research Excellence in 1999. Then, he became an associate professor in Osaka Medical College, Osaka, Japan and conducted cancer research and medical education at this medical college in 1999-2011.

Researches :

  • Anatomy and Cell Biology
Lucy
Dr Stefano Iotti
University of Bologna

Biography

Professor of Biochemistry at the University of Bologna. Since 1990 he has contributed to the development of in vivo magnetic resonance spectroscopy in basic research and in diagnostic applications. In 1987 he gained his master’s degree in Chemistry, and PhD in Biochemistry in 1994. From 1992 to 1993 he has been working at the Department of Biochemistry and Biophysics of the University di Pennsylvania. His scientific activity ranged from organic and physical chemistry to biochemical thermodynamics. At present part of the activity is directed to the study of magnesium homeostasis in living human tissues and in vitro in cell culture. He contributed to the development of a novel procedure to simplify the treatment of the thermodynamics of complex systems making possible to re-unify the two worlds of chemical and biochemical thermodynamics, which so far have been treated separately, and represents a new paradigm in the biochemical thermodynamics

Researches :

  • Biochemistry, Biochemical thermodynamics, Physical chemistry, Cell imaging, Alternative medicine, Science and art integration, Effect of sound on living systems
Lucy
Dr NORIMUNE KAWAI
Hiroshima University Kagamiyama

Biography

Dr. Norimune (Nori) Kawai, CCC-SLP, is an Professor in the Center for Special Needs Education Research and Practice, Graduate School of Education at Hiroshima University, Japan. His research topics are listeners auditory perceptions of stuttering and speech motor activities of people who stutter. Although his primary area of interest involves fluency disorders, Nori spends more than 600 hours to deal with children and adults who have various kinds of speech, language, and hearing disorders every year in addition to his teaching and research hours.

Lucy
Dr Arthur Yin Fan
McLean Center for Complementary and Alternative Medicine

Biography

Arthur yin Fan,PhD,CMD,LAc. An active researcher in Acupuncture and Oriental medicine(AOM).Director of McLean Center for Complementary and Alternative Medicine, PLC. Research adviser for Acupuncture and Traditional Chinese Medicine program,Center for Integrative Medicine, University of Maryland. Research interests: AOM Basic study, acupuncture mechanism, herb safety evaluation, AOM clinic trial design and methodology,and AOM history.

Researches :

  • Scientific study, clinical practice and history of Acupuncture,Chinese medicine(herbology)
Lucy
Dr Soren Ventegodt
Quality of Life Research Center

Biography

Dr. Søren Ventegodt was born in 1961. His father was a historian specialised in maritime history and co-editor of the large Gyldendal Danish Encyclopaedia, his mother a nurse with a master degree in French. When Søren was 10 years old his younger brother Jesper died in a terrible drowning accident, which awakened Søren’s spiritually and he soon became interested in philosophy, science, sport and arts. At age 11 years, he started to write poetry, play music and read books on chemistry and at age 13 years he had his own chemistry lab in the family basement, which he continued to develop though his teenage years. Gifted with a special talent for science he entered the University of Copenhagen at age 18 years and after studying chemistry, philosophy and finally medicine, he entered the research field of theoretical biology. During his last years at the university he developed a highly controversial theory of quality of life (QOL) and the state of consciousness as the primal factors causing disease including cancer. His research in quality of life soon became popular with the general public and in 1992 the Pharmacist Foundation of 1991 awarded him, while still a medical student, a grant of 600,000 Euro for his research in quality of life and health. The University Hospital in Copenhagen (Rigshospitalet) and the late pediatric professor Bengt Zachau-Christiansen helped him to establish the Quality of Life Survey using the Copenhagen Perinatal Birth Cohort 1959-61 as the sample for the research. This way the Quality of Life Research Center (QOLRC) was established in 1993 at the University Hospital. In 1994 this institution became one of the first independent QOL Research Centers in Northern Europe and moved to its present location in the center of old Copenhagen with Søren as its director. In 1997 the Research Clinic for Holistic Medicine was established. More than 100 peer reviewed scientific papers have now been published, making the QOLRC one of the worlds most productive centres of new medical knowledge in the field of clinical holistic medicine – “quality of life as medicine”. In 2003 the Scandinavian Research Institute for Working Life Quality (NFA) was established in Oslo, Norway based on the ideas, books and materials produced by Søren Ventegodt. In 2004 the Nordic School of Holistic Medicine was established at the QOLRC. He also participated in establishing the International Society for Holistic Health (ISHH) in 2004. In 2006 he became director of Nordic Campus, Interuniversity College, Graz. Søren Ventegodt is today the author of 10 popular books (some of them best sellers) and hundreds of papers and articles in magazines and scientific journals. He is often used as a speaker on QOL and holistic health throughout the Nordic countries. Through more than 1,000 presentations and lectures at most of the universities and large companies in Denmark he has made 100,000 Danes understand the fundamental quality of life concepts. After more than 1,000 presentations in the national medias, from the nine a clock news to national TV- and radio programs and the front pages of the leading newspapers during the past 14 years, the Danish society at large now seems to have assimilated the key message: that you can improve your QOL and thus prevent disease and even improve your health and ability if you are sick, unhappy or poorly functioning. He is also working on several international text book series i.e. “The Principles of Holistic Medicine” together with professor Joav Merrick, MD, DMSc. He is a permanent member of the organizing committee arranging international conferences on Holistic Health together with the ISHH (International Society for Holistic Health), which he initiated in Copenhagen in 2004. His most ambitious project is starting a holistic research hospital and he is working to raise the funds needed for the establishment. The hospital will take the scientific holistic medicine to the next level, which is the phase 3 clinical studies, documenting the effect of the new drug-free medicine on a large number of patients with many different diseases from cancer, autoimmune diseases, and chronic pains to schizophrenia and existential, developmental and psycho-sexual problems. His dream is that in 2030 many more physicians will use holistic training programs to help their patients fight the diseases instead of just giving bio-medical drugs, which often is not effective with chronic illness.

Researches :

  • human sexuality and treatment of sexual problems and dysfunctions.
Lucy
Dr Paolo Gisondi
University Hospital of Verona

Biography

Dr. Paolo Gisondi was born in Rome in 1972. He is married with Emanuela and is the father of Marco. He currently works as a research assistant in the Dermatology and Venereology Section of the University Hospital of Verona, Italy. He received his degree in Medicine from the Catholic University of Rome in 1997 and then specialized in Dermatology and Venereology at the University of Parma in 2002. Before moving to Verona in 2006, he worked for two years at the Istituto Dermopatico dellImmacolata of Rome. He is a member of the Italian Society of Dermatology (SIDEMAST), European Academy of Dermatology and Venereology (EADV), Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and he has been invited to join to the European Dermato-epidemiology Network (EDEN). He is an editorial board member of the Open Journal of Dermatology, World Journal of Diabetes and Advances in Psoriasis and Inflammatory Skin Diseases. He has been sub-investigator in 15 clinical phase III randomized trials investigating the effects of biological therapies in psoriasis. His main scientific interests include the epidemiological, clinical (i.e. comorbidities) and therapeutic aspects of psoriasis and psoriatic arthritis. Apart from clinical research, more than half of his working hours are dedicated to the outpatient clinic and dermatological surgery. He is a co-author of 80 original articles, 14 book chapters, 88 abstracts for congresses and 80 invited lectures.

Researches :

  • Alternative & Integrative Medicine.
Lucy
Dr Olga Golubnitschaja
University in Bonn

Biography

Dr. Olga Golubnitschaja has studied journalism, biotechnology and medicine and was awarded fellowships for biomedical research in Paediatrics and Neurosciences (Medical Centres in Austria, Russia, UK, Germany, The Netherlands, and Switzerland). She is well-cited in the research fields of “gene hunting” and “subtractive hybridisation” applied to predictive prenatal & postnatal diagnostics published as O.Labudova in years 1990-2000. Dr. Golubnitschaja is an expert in molecular diagnostics actively publishing in the fields of perinatal diagnostics, Down Syndrome, Diabetes mellitus, hyperhomocysteinemia, cardiovascular disease, neurodegeneration, cancer. She is the author of fundamental works in the integrative concept of predictive, preventive and personalised medicine. She is Secretary-General of the European Association for Predictive, Preventive & Personalised Medicine (EPMA, Brussels), Editor-in-Chief of "The EPMA-Journal", BMC, London, Book Editor of "Predictive Diagnostics & Personalised Treatment: Dream or Reality", NSP, New York 2009; Book-Series Editor "Advances in Predictive, Preventive & Personalised Medicine", Springer.  

Researches :

  • Integrative concept of predictive, preventive and personalised medicine